


The goal of prediction of autoimmune diseases is prevention and/or early intervention to avert morbidity and mortality. In most diseases with an autoimmune pathology, a long prodrome is associated with the production of disease specific autoantibodies and may provide a window of opportunity to reverse the autoimmune process. However, large prospective studies are necessary to evaluate the risk of disease development in autoantibody positive persons. In type 1 diabetes, autoantibody assays make it possible to accurately identify people at risk of future disease. A similar development can be promised for rheumatoid arthritis. Therefore, both diseases may serve as models for prevention and novel treatment strategies. A prerequisite for prevention and curative therapy is the very early or even predictive diagnosis employing by biomarker analyses. The improvement, optimization and standardization of autoantibody determinations combined with evaluation studies play an important role in this process. This current volume will focus on different aspects of the pathogenesis, the prediction, novel treatment regimes and prevention of systemic and organ specific autoimmune diseases as well as autoimmune graft rejections. Rare autoimmunopathies such as autoimmune forms of thrombotic microangiopathies, nephropathies, myopathies and cardiomyopathies are also included.

From Prediction to Prevention of Autoimmune Diseases
K. Conrad, E. K. L. Chan, M. J. Fritzler, R. L. Humbel, P. L. Meroni, Y. Shoenfeld (Eds.)

K. Conrad, E. K. L. Chan, M. J. Fritzler, R. L. Humbel,
P. L. Meroni, Y. Shoenfeld (Eds.)

From Prediction to Prevention of Autoimmune Diseases

Report on the 10th Dresden Symposium on Autoantibodies
held in Dresden on September 22–25, 2011



AUTOANTIGENS, AUTOANTIBODIES, AUTOIMMUNITY
Volume 7 – 2011

ISBN 978-3-89967-735-5
www.pabst-publishers.com



PABST

From Prediction to Prevention of Autoimmune Diseases
Report on the 10th Dresden Symposium on Autoantibodies

K. Conrad, E. K. L. Chan, R. L. Humbel, P. L. Meroni, Y. Shoenfeld (Eds.)



Gesellschaft zur Förderung der Immundiagnostik e.V.
Dresden
<http://www.GFID-eV.de>

AUTOANTIGENS, AUTOANTIBODIES, AUTOIMMUNITY

Edited by: K. Conrad (Dresden, Germany)

Vol. 7 — 2011

K. Conrad, E. K. L. Chan, R. L. Humbel,
P. L. Meroni, Y. Shoenfeld (Eds.)

From Prediction to Prevention of Autoimmune Diseases

Report on the 10th Dresden Symposium on Autoantibodies held in Dresden
on September 22–25, 2011

AUTOANTIGENS, AUTOANTIBODIES, AUTOIMMUNITY
Volume 7 — 2011



PABST SCIENCE PUBLISHERS
Lengerich, Berlin, Bremen, Miami,
Riga, Viernheim, Wien, Zagreb

Bibliographic information published by Deutsche Nationalbibliothek
The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data is available in the Internet at <<http://dnb.ddb.de>>.

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in other ways, and storage in data banks. The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulation and therefore free for general use.

The authors and the publisher of this volume have taken care that the information and recommendations contained herein are accurate and compatible with the standards generally accepted at the time of publication. Nevertheless, it is difficult to ensure that all the information given is entirely accurate for all circumstances. The publisher disclaims any liability, loss, or damage incurred as a consequence, directly or indirectly, of the use and application of any of the contents of this volume.

© 2011 Pabst Science Publishers, 49525 Lengerich

<http://www.pabst-publishers.de>

Printing: MercedesDruck, Berlin
Typesetting: Hilmar Schlegel, Berlin
Cover: Claudia Döring, Lengerich

ISBN 978-3-89967-735-5

Contents

Preface XIX

Chapter 1 From Prediction to Prevention of Autoimmune Diseases

- 1 From prediction to prevention of autoimmune diseases – Role of autoantibodies 2
Karsten Conrad
- 2 Distinctive features of autoantibodies in and out the context of overt autoimmunity 16
Alessandra Dellavance, Henrique A. Mariz, Silvia Helena Barbosa, Eduardo L. R. Caçado, Emilia I. Sato, Luís Eduardo C. Andrade
- 3 Antibody proteases as preclinical diagnostic and predictive tools in multistep monitoring clinical autoimmunity conditions 37
Sergey Suchkov, Aleksander Gabibov, Mihail Paltsev
- 4 The role of Vitamin D in immunologic homeostasis and prevention of disease 63
Yoav Aronson, Yehuda Shoenfeld, Nancy Agmon-Levin, Howard Amital
- 5 The role of miRNAs in the regulation of immunological functions and the prevention of autoimmunity 75
Edward K. L. Chan, Angela Ceribelli, and Md A. Nahid
- 6 ASIA – Autoimmune Syndrome Induced by Adjuvants – confirmations, experimental data and mechanisms 90
Yehuda Shoenfeld, Nancy Agmon-Levin
- 7 Prognostic value of antibodies to oxydized low-density lipoprotein in acute coronary syndrome and stable coronary artery disease 100
S. Sipka, R. Laczik, I. Csipo, P. Szodoray, S. jr. Sipka, M. Szokol, P. Soltesz
- 8 Long Pentraxin PTX3 and autoantibodies production in autoimmune diseases 102
S. Valaperta, M. Monari, C. Alpini, E. Baldassarre, F. Gioia, A. Montanelli
- 9 Autoantibodies against chaperonin CCT in glomerular immune deposits and sera in patients with membranous nephropathy: possible role in disease progression 105
Florence Lefeu, Fabienne Fasani, Chantal Jouanneau, Pierre Ronco, Hanna Debiec

- 10 Autoantibodies to cytoplasmic rod/ring structure targeting CTP/GTP synthetic pathway in HCV patients treated with interferon/ribavirin 107
W.C. Carcamo, A. Ceribelli, G. Covini, C.A. von Mühlen, C. Liu, M. Satoh, E.K.L. Chan

1.1 Diabetes Mellitus Type 1

- 11 Type 1 diabetes – a model for disease prediction and prevention 110
Matthias von Herrath and Ghanashyam Sarikonda
- 12 Patient derived human monoclonal islet autoantibodies in Type 1 Diabetes 117
Mara Catani, Denise Walther, Stephanie Krause, Michael Christie, Vito Lampasona, Ezio Bonifacio, Anne Eugster
- 13 Sunset of routine diagnostics of ICA? 119
Jan Martinek, Ivo Lochman, Alexandra Lochmanova

1.2 Rheumatoid Arthritis

- 14 From prediction to prevention of rheumatoid arthritis 122
Karin Lundberg
- 15 Personalized medicine approaches in rheumatoid arthritis and other systemic autoimmune rheumatic diseases 127
Marvin J. Fritzler
- 16 Value of the ACR Guidelines for the diagnosis of RA 138
Manfred Herold
- 17 Anti-RA33 – New data on a marker linked to ACPA-negative rheumatoid arthritis with a mild prognosis 141
Günter Steiner, Karl Skriner, Elisabeth Höfler, Christian Löbke, Klaus P. Machold, Josef Smolen
- 18 Auto-antibodies recognizing carbamylated proteins are frequently present in sera of patients with rheumatoid arthritis and predict radiological joint damage 143
J. Shi, R. Knevel, P. Suwannalai, M.P. van der Linden, G.M.C. Janssen, P. van Veelen, E.W. Levarht, A.H. van der Helm-van Mil, A. Cerami, T.W.J. Huizinga, R.E. Toes, L.A. Trouw

19	Novel autoantibody markers for early and seronegative rheumatoid arthritis <i>Klaartje Somers, Piet Geusens, Dirk Elewaut, Filip De Keyser, Jean-Luc Rummens, Marieke Coenen, Marlies Blom, Piet Stinissen and Veerle Somers</i>	145
20	Development and optimization of a sensitive peptide ELISA for autoantibody testing in early and seronegative RA <i>Liesbeth De Winter, Klaartje Somers, Piet Geusens, Dirk Elewaut, Piet Stinissen and Veerle Somers</i>	177
21	Early arthritis and biomarkers: a proposal of diagnostic profile gender oriented <i>T. Castagno, M. Nastro, C. Nastro, I. Soriente, P. Amato, P. Sabatini</i>	179
22	Anti-citrullinated fibronectin antibodies in rheumatoid arthritis are associated with HLA-DRB1 shared epitope alleles <i>Joyce J.B.C. van Beers, Annemiek Willemze, Rene E.M. Toes and Ger J. M. Pruijn</i>	181
23	On the role of nucleic acids and their binding proteins in the pathogenesis of autoimmune arthritis in rats, mice and men <i>Günter Steiner</i>	183
24	Evaluation of the Zenit RA for the detection of citrullinated protein antibodies <i>An-Sofie Decavele, Carolien Bonroy</i>	186
25	Evaluation of the measurement of anti-CCP antibodies by 2 methods: INOVA anti-CCP3 ELISA assay and BioPlex® 2200 Multiplex assay <i>Raya Harich, Nicole Fabien</i>	188

1.3

Connective Tissue Diseases, Systemic Vasculitides and Antiphospholipid Syndrome

26	Novel autoantibodies, clinical phenotypes and pathogenesis of idiopathic myopathies <i>Zoe E. Betteridge, Harsha Gunawardena and Neil J. McHugh</i>	192
27	Anti-Mup44: the first inclusion body myositis-specific autoantibody <i>Helma Pluk, Baziel G. van Engelen, Ger J. M. Pruijn</i>	210
28	Novel Autoantibodies to EIF3 in polymyositis <i>Zoe E. Betteridge</i>	211
29	Rapid progressive autoimmune myositis – case report <i>Marten Kayser, Markus Enderlein, Leonore Unger</i>	213

- 30 Epstein-Barr virus diffuse early antigen directed immunoglobulin A antibodies in systemic lupus erythematosus 215
Anette Holck Draborg
- 31 Anti-dsDNA antibody production is restricted by the germline composition of DH genes 216
A. Silva-Sanchez, C.-R. Liu, P. Kapoor, Y. Zhuang, T. Schoeb, H. W. Schroeder, Jr.
- 32 Role of functional antibodies against vascular receptors in systemic sclerosis 218
Mike O. Becker, Angela Kill, Reinmar Undeutsch, Christoph Tabeling, Martin Witzernath, Wolfgang M. Kuebler, Sebastian Bock, Rudi Sampati, Harald Heidecke, Ivo Lukitsch, Duska Dragun, Gabriela Riemekasten
- 33 Role of agonistic autoantibodies directed to the angiotensin II type 1 and the endothelin-1 type A receptors in systemic sclerosis 226
Angela Kill, Jeannine Günther, Mike O. Becker, Harald Heidecke, Duska Dragun, Gabriele Riemekasten
- 34 Systemic Sclerosis – agonistic autoantibodies directed against the angiotensin receptor type 1 and the endothelin receptor type A and their effects on immune cells 228
J. Günther, J.A. Calatayud Subias, A. Kill, M.O. Becker, G. Riemekasten
- 35 Anti-tubular basement membrane antibodies: A new pathognomonic parameter in the serological diagnosis of progressive systemic sclerosis 230
Kristin Rentzsch, Anthonina Ott, Wolfgang Meyer, Sandra Saschenbrecker, Wolfgang Schlumberger, and Winfried Stöcker
- 36 PLA2 receptor antibodies as serological markers of idiopathic membranous nephritis are absent in active membranous lupus nephritis 232
Iva Gunnarsson, Wolfgang Schlumberger, Johan Rönnelid
- 37 Identification of ATP-binding cassette transporter protein F1 (ABC-F1) as a novel autoantigen 234
M. Blüthner, M. Volkmann, H. Appelhans, I. Moosbrugger, C. Wiemann, C. Becker, H.P. Seelig
- 38 Validation of Bio-Rad vasculitis assays for use on the Evolis™ and Evolis™ twin plus microplate systems 237
Raisa Lerner, Xiaowen Guo, Wendy Vandam and Tony Prestigiacomo
- 39 Validation of Bio-Rad vasculitis assays for use on the PhD™ and PhD™ LX IFA/EIA systems 239
Raisa Lerner, Xiaowen Guo, Wendy Vandam and Tony Prestigiacomo

-
- 40 Performance of a novel chemiluminescence assay for the detection of PR3- and MPO-ANCA: Comparison with ELISA methods 241
Michael Mahler, Andrea Seaman, Elena Csernok, Renato A. Sinico, Antonella Radice
- 41 Antiphospholipid syndrome: not only an antibody-mediated disease 243
Roberta Gualtierotti, M. Orietta Borghi, Elena Raschi, Francesco Tedesco, Pier Luigi Meroni
- 42 Anti-vimentin/cardiolipin complex autoantibodies in antiphospholipid syndrome: preliminary data using a new ELISA method 263
F. D'Aurizio, M. Fabris, R. Giacomello, J. Peresan, D. Visentini, F. Curcio, E. Tonutti
- 43 Autoantibodies against galectins as novel biomarkers for the antiphospholipid syndrome? 266
Christina Janko, Christine Schorn, Silke Winkler, Ricardo Chaurio, Luis E. Munoz, Sylviane Muller, Hans-Joachim Gabius, Georg Schett, and Martin Herrmann

1.4

Neurological Diseases

- 44 Neurofilament heavy chains and antibodies against them as markers for axonal damage in patients with multiple sclerosis 268
L. Fialová, A. Bartoš, J. Švarcová, D. Zimová, I. Malbohan
- 45 Relationship between neurofilament light chains and antibodies against them in cerebrospinal fluid in patients with multiple sclerosis 271
J. Švarcová, L. Fialová, A. Bartoš, D. Zimová, I. Malbohan
- 46 Peripheral and intrathecal immortalized B cells from multiple sclerosis patients show clonal expansion and produce autoreactive antibodies 274
J. Fraussen, K. Vrolix, P. Martinez-Martinez, M. Losen, R. Hupperts, B. van Wijmeersch, M.H. De Baets, P. Stinissen and V. Somers
- 47 Discovery of novel antigenic targets for Clinically Isolated Syndrome 276
M. Rouwette, K. Somers, C. Govarts, R. Hupperts, B. van Wijmeersch, B. de Jong, M. Verbeek, V. van Pesch, C. Sindic, L. Villar, P. Stinissen and V. Somers

48	Anti-neurofascin autoantibodies: Assay development and analysis of inflammatory diseases of the CNS and PNS	278
	<i>Judy King Man Ng, Joachim Malotka, Naoto Kawakami, Tobias Derfuss, Mohsen Khademi, Tomas Olsson, Philipp Sämann, Frank Weber, Masaaki Odaka, Nobuhiro Yuki, Björn Tackenberg, Johannes Brettschneider, Matthew Rasband, Christopher Linington, Harald Prüss, Jan Schwab, Reinhard Hohlfeld, Hartmut Wekerle, Klaus Dornmair, Edgar Meinl</i>	
49	Isaac's syndrome – casuistry	281
	<i>V. Novák, J. Junkerová</i>	
50	Identification of linear epitopes of HuD antibodies related to paraneoplastic diseases	283
	<i>Nicole Petersen</i>	
51	Anti-neuronal antibodies in the request context – an annual evaluation of a medical laboratory	285
	<i>V. Jansen, R. Tripmacher, A. Jagiello, R. Moog, S. Tobisch, R. Lange</i>	

1.5 Gastrointestinal and Liver Diseases

52	Novel autoantibody markers in autoimmune gastrointestinal and liver diseases	288
	<i>Dimitrios P. Bogdanos, Karsten Conrad, Daniel S. Smyk, Eirini I. Rigopoulou and Alastair Forbes</i>	
53	Autoantibodies to GP2 – A new marker for Crohn's disease	302
	<i>Dirk Roggenbuck, Dirk Reinhold, Thomas Wedx, Alexander Goihl, Ulrike von Arnim, Peter Malfertheiner, Thomas Büttner, Tomas Porstmann, Silvia Porstmann, Bodo Liedvogel, Dimitros P. Bogdanos, Martin W. Laas, Karsten Conrad</i>	
54	Determination of anti-deamidated gliadin/anti-tissue transglutaminase antibodies in patients with anti-gliadin and anti-cow's milk antibodies	304
	<i>Miroslav Hindoš, Karin Malíčková, Ivana Janatková</i>	
55	Occurrence of anti-alpha-fodrin antibodies in patients with Crohn's disease	306
	<i>G. Nagy, M. Papp, I. Csipo, S. Sipka</i>	
56	Unusual B cells line in inflammatory bowel disease	308
	<i>Caterina Defendenti, Silvia Grosso, Fabiola Atzeni, Annamaria Croce, Olivia Senesi, Simone Saibeni, Simona Bollani, Piero Luigi Almasio, Savino Bruno and Piercarlo Sarzi Puttini</i>	

- 57 Anti-asialoglycoprotein receptor antibody measured by ELISA is a specific marker of liver autoimmunity and mirrors disease activity in patients with autoimmune hepatitis 311
Maria G. Mytilinaïou, Dirk Roggenbuck, Tassos Grammatikopoulos, Edward T. Davies, Ourania Romanidou, Eirini I. Rigopoulou, Ian MacFarlane, Giorgina Mieli-Vergani, Diego Vergani, Dimitrios P. Bogdanos
- 58 Relevance of M2 IgG, IgM & IgA antibodies in primary biliary cirrhosis 313
S. Swinarski, R. Klein, H. Ohira, T. Ostler
- 59 Evaluation of the diagnostic performance of an enzyme immunodot blot for the detection of anti-actin autoantibodies in patients with autoimmune hepatitis 315
B. Schlüter, J. Schmalhorst, P. Willeke, H. Schotte

1.6

Autoimmune Heart Diseases

- 60 Chronic Chagas' heart disease – from pathogenesis to treatment regimes 318
Silvia Gilka Munoz-Saravia, Annekathrin Haberland, Gerd Wallukat, and Ingolf Schimke
- 61 Dilated cardiomyopathy (DCM) and myocarditis: classification, clinical and autoimmune features 354
Alida L.P. Caforio, Stefania Bottaro, Sabino Iliceto
- 62 Pathophysiology of autoimmune-associated congenital heart block 371
Yongxia Qu, Mohamed Boutjdir

1.7

Autoimmune Thrombotic Microangiopathies

- 63 The anti-factor H autoantibody-associated hemolytic uremic syndrome 394
Marie-Agnès Dragon-Durey
- 64 Autoimmune forms of complement associated kidney disorders 403
Peter F. Zipfel, Chen Qian, Dominik Müller and Christine Skerka
- 65 Atypical hemolytic uremic syndrome-associated anti-factor H autoantibodies inhibit factor H binding to pentraxin 3 412
Anne Braunschweig, Stefanie Strobel, Mihály Józsi

1.8**Autoimmune graft rejection**

- 66 Humoral autoimmunity in transplantation 416
Gavin Pettigrew
- 67 Alloimmunity induced autoimmunity: role in the pathogenesis of chronic allograft rejection 433
Vijay Subramanian, Thalachallour Mohanakumar
- 68 Activating autoantibodies against the AT1-receptor in vascular disease 446
Ralf Dechend, Duska Dragun, Florian Herse, Gabriele Riemekasten, Kai Schulze-Forster, Dominik N Müller, Harald Heidecke

Chapter 2**Perspectives in the Treatment of Autoimmune Diseases**

- 69 Therapeutic concepts of targeting plasma cells 458
Falk Hiepe
- 70 Aptamer-based immunotherapy 466
A. Haberland, G. Wallukat, C. Dahmen, A. Kage, I. Schimke
- 71 A decade of peptide-based immunotherapy for autoimmune diseases 475
Oscar-Danilo Ortega-Hernandez, Yehuda Shoefeld, Miri Blank
- 72 Prophylactic and therapeutic application of a new vaccination technique for combating autoimmune disorders 519
Arpad Zsigmond Barabas, Chad Douglas Cole, Rene Lafreniere, Donald Mackay Weir
- 73 Attenuation of autoimmunity by anti-human-interleukin-17 aptamer in mouse models 540
Yoshikazu Nakamura, Hironori Adachi, Akira Ishiguro
- 74 Autoantibody secreting cells in the nephritic kidneys of lupus prone NZB/W F1 mice are sensitive to bortezomib 542
Charlotte Starke, Vilma Urbonaviciute, Silke Frey, Georg Schett, Reinhard E. Voll
- 75 Construction and production of synthetic competitors for suppression of the activity of immune complexes causing IgA nephropathy 544
Alena Kasperova, Lydie Czernekova, Katerina Zachova, Milada Horynova, Jan Novak, Jiri Mestecky, Ivan Sterzl, Milan Raska

76	Diagnostic of latent form of tuberculosis before anti TNF-treatment <i>E. Záhová, D. Kozáková, V. Pol'anová, I. Solovič, J. Rybár, F. Máliš, J. Rovenský,</i>	545
77	High frequency immunoadsorption may reduce autoantibodies and improve lung disease in systemic sclerosis (SSc) – lessons from a first case <i>Nicolai Leuchten, Karsten Conrad, Kerstin Johne, Ulrich Julius, Martin Aringer</i>	547
78	Oxidized ATP inhibits T-cell-mediated autoimmunity <i>Carmen Barthuber, Philipp A. Lang, Karl S. Lang</i>	549
79	Clinical impact of neutralizing antibodies against TNF-alpha inhibitors <i>Arno Kromminga</i>	551
80	Formation of antiphospholipid antibodies and antibodies to infliximab in anti-TNF-alpha antibody-treated patients with inflammatory bowel diseases <i>Karin Malíčková, Ivana Janatková, Naděžda Machková, Dana Duricová, Martin Bortlík, Tomáš Zima, Milan Lukáš</i>	556

Chapter 3 Diagnostics of Autoimmune Diseases

3.1 Autoantibody Determinations – History and Perspectives

81	History of autoimmune serology <i>René-Louis Humbel</i>	563
82	Rheumatoid Factors after 70 years – Why cannot be still expected standardization of their determination? <i>Ivo Lochman, Alena Kloudová, Alexandra Lochmanová, Vítězslav Novák, Jan Martinek, Hana Tomášková, Ivana Pütová, Ladislav Cebecauer</i>	575
83	Autoantibody testing: current challenges and future opportunities <i>Marvin J. Fritzler</i>	584
84	ANCA testing: Current stage and perspectives <i>Elena Csernok</i>	597
85	Recent advances in peptide resolved diagnostics of systemic autoimmune diseases <i>Michael Mahler, Walter L Binder and Marvin J Fritzler</i>	598

- 86 Comparative analysis of sera reacting with linear peptides and recombinant proteins 626
Felix Steinbeck, Nadine Born, Peter Lorenz, Björn Ziem, Johannes Wollbold, Michael Hecker, Michael O. Glocker, and Hans-Jürgen Thiesen
- 87 Enhanced Biobanking – a prospective approach for the procurement of human biomaterial for the diagnostic industry 628
Joerg-M. Hollidt, Robert Lange
- 88 Development of an interface connecting the mobile reader system OpTrilyzer® to HL-7 hospital information systems for the use in autoimmune diagnostics 630
Dennis Krischok, Robert Lange, Volker Plickert, Lutz Melchior, Joerg-M. Hollidt, Frauke Adams

3.2

Role of Immunofluorescence in Autoantibody Detection

- 89 Multi-centre collaboration is needed to reach a unified and strictly defined classification of IIF ANA patterns 634
Allan Wiik, Peter Charles, Jan Meyrowitsch
- 90 Challenges of automated screening and differentiation of non-organ specific autoantibodies on HEp-2 cells 647
Rico Hiemann, Thomas Büttner Thorsten Krieger Dirk Roggenbuck, Ulrich Sack, Karsten Conrad
- 91 Automated interpretation of antinuclear antibody assessment on HEp2-cells by standardized algorithms 660
Karl Egerer, Dirk Roggenbuck, Rico Hiemann, Max-Georg Weyer, Thomas Büttner, Boris Radau, Rosemarie Krause, Barbara Lehmann, Eugen Feist, Gerd-Rüdiger Burmester
- 92 Digital image analysis results show high reproducibility and agreement with human interpretation on HEp-2 cells 662
Carol Buchner
- 93 Comparison of an ANA automated reading system with conventional fluorescence microscopy 664
Thorsten Krieger
- 94 Assessment of the CTD-screen Phadia-EliA and of the ANA screening assay in the routine clinical laboratory of a general hospital 666
Milca Geane de Lamos Valim

-
- 95 Clinical evaluation of EliA CTD Screen in CTD patients and control samples in comparison to ANA immunofluorescence (IIF) on HEp-2 cells 668
Markku Viander, Marja Hietarinta and Jussi Kantele
- 96 Redefining ANA testing: Development of a highly specific ANA HEp-2 test based on immunoabsorption of anti-DFS70 autoantibodies 671
Michael Mahler, Andrea Seaman, Todd Parker, Aaron Llanes, Carol L. Peebles, John G. Hanly, Marvin J. Fritzler
- 97 ANA immunofluorescence patterns and their association with reactivity to molecularly defined nuclear targets in children with type 1 autoimmune hepatitis 673
Maria G. Mytilinaiou, Bianca Teegen, Tassos Grammatikopoulos, Edward T. Davies, Eirini I. Rigopoulou, Lars Komorowski, Wolfgang Meyer, Cornelia Dährnich, Giorgina Mieli-Vergani, Kai Fechner, Diego Vergani, Dimitrios P. Bogdanos
- 98 Cytoplasmic ring/rod autoantibodies in patients undergoing screening for antinuclear antibodies (ANA) 676
P. Congedo, C. Defendenti, S. Finazzi, E. Arighi, C. Colzani, F. De Filippi, M. Lotzniker, A. Papa, G. Spinzi, R. Terramocci, N. Terreni
- 99 Standardized detection of anti-ds DNA antibodies by indirect immunofluorescence – A new age for confirmatory tests in SLE diagnostics 678
Dirk Roggenbuck, Dirk Reinhold, Rico Hiemann, Ursula Anderer, Thomas Büttner, Karsten Conrad
- 100 Computer-Aided Immunofluorescence Microscopy (CAIFM) in the diagnosis of autoimmune and infectious diseases 680
Winfried Stöcker, Martin Rateike, Markus Morrin, Jörn Voigt, Kristin Rentzsch, Christopher Krause, Konstantin Ens, Hendrik Fauer, Erhardt Barth, Christian Feirer, Daniel Wuttig, Kai Fechner, Steffen Kloth and Thomas Martinetz
- 101 Automatic reading of ANCA-slides: evaluation of the AKLIDES system 683
Jan Damoiseaux, Kathleen Mallet, Mia Vaessen, Jos Austen, and Jan Willem Cohen Tervaert
- 102 Performance of the automated immunofluorescence system AKLIDES® for detection of antineutrophil cytoplasmic antibodies 685
Ilka Knütter, Rico Hiemann, Therese Brumma, Thomas Büttner, Kai Großmann, Dirk Roggenbuck, Dirk Reinhold, Elena Csernok
- 103 Autoantibody detection in bullous pemphigoid: comparison of sensitivity and specificity of different diagnostic techniques 687
Jan Damoiseaux, Margit van Rijsingen, Nicole Warnemünde, Cornelia Dährnich, Jan Willem Cohen Tervaert, Kai Fechner, Pamela Poblete-Gutiérrez

3.3

Novel Assays for Autoimmune Diagnostics

- 104 A new ELISA test for the detection of the monoclonality of anti-MAG antibodies 690
Arnaud Quittard-Pinon, Bernhard Mani, Renato Cotti, Jérôme Fernandez, Christiane Caudie
- 105 Detection of conformation-specific autoantibodies to transglutaminase 6 in neurology patients 692
P. Aeschlimann, M. Hadjivassiliou, M. Hils, J. Weber, R. Pasternack, M. Adamczyk, K. Beck and D. Aeschlimann
- 106 New sensitive and reliable Lateral Flow Assays for the detection of proteinase 3 and myeloperoxidase antibodies 694
J. Schulte-Pelkum, R. Lucassen, M. Petschinka and M. Fooke
- 107 Development of anti-type VII collagen ELISA for the diagnosis and monitoring the disease activity of epidermolysis bullosa acquisita patients 696
Akihiro Murakami
- 108 Development of ELISA to detect anti-aminoacyl-tRNA synthetase autoantibodies for the diagnosis of myositis and interstitial pneumonia 698
Akihiro Murakami

3.4

Multiplex Immunoassays – Autoantibody Profiling

- 109 Profiling of antiphospholipid antibodies – association with cerebrovascular events in antiphospholipid syndrome (APS) 702
Karl Egerer, Dirk Roggenbuck, Thomas Büttner, Barbara Lehmann, Annushka Kohn, Philipp von Landenberg, Eugen Feist, Gerd-Rüdiger Burmester, Thomas Dörner
- 110 Multiparametric detection of anti-ganglioside antibodies by 5 commercial immunoassays in patients with well-characterized immune-mediated peripheral neuropathies 704
Christiane Caudie, Arnaud Quittard Pinon, Françoise Bouhour, Christophe Vial, Nicole Fabien
- 111 Multiparametric serological testing in autoimmune encephalitis using a recombinant immunofluorescence assay and EUROIDE technology 706
Klaus-Peter Wandinger, Christine Klingbeil, Patrick Waters, Josep Dalmau, Sandra Saschenbrecker, Kathrin Borowski, Angela Vincent, Christian Probst, Winfried Stöcker

112	Detection of autoantibodies in pemphigus, bullous pemphigoid, and epidermolysis bullosa acquisita by indirect immunofluorescence with a Biochip™ mosaic	709
	<i>Christian Probst, Inga-Madeleine Blöcker, Winfried Stöcker, Enno Schmidt, Detlef Zillikens, Lars Komorowski</i>	
113	Improvement in routine laboratory protocols for systemic sclerosis	711
	<i>M. Lotzniker, S. Finazzi, G. Re, S. Forlani, P. Faggioli</i>	
114	Validation of a single multiparameter lineblot for the detection of systemic sclerosis-associated autoantibodies	713
	<i>Carolien Bonroy, Jens Van Praet, Vanessa Smith, Katleen Van Steendam, Tsuneyo Mimori, Ellen Deschepper, Dieter Deforce, Katrien Devreese and Filip De Keyser</i>	
115	Multiplex autoantibody detection for serological diagnosis of systemic vasculitides	715
	<i>Kai Großmann, Rico Hiemann, Annika Willitzki, Therese Brumma, Ilka Knütter, Dirk Reinhold, Ulrich Sack, Karsten Conrad, Elena Csernok, Dirk Roggenbuck</i>	
	Subject Index	719
	Author Index	723

Preface

The goal of prediction of autoimmune diseases is prevention and/or early intervention to avert morbidity and mortality. In most diseases with an autoimmune pathology, a long prodrome is associated with the production of disease specific autoantibodies and this may provide a window of opportunity to reverse the autoimmune process. However, large prospective studies are necessary to evaluate the risk of disease development in autoantibody positive persons. In type 1 diabetes, autoantibody assays make it possible to accurately identify people at risk of future disease. A similar development can be promised for rheumatoid arthritis. Therefore, both diseases may serve as models for prevention and novel treatment strategies. A prerequisite for prevention and curative therapy is the very early or even predictive diagnosis employing biomarker analyses as well as the better understanding of the etiopathogenesis of autoimmune diseases including the interplay between genetic and environmental factors in initiating and maintaining pathogenic autoimmune responses. This current volume will focus on different aspects of the pathogenesis, the prediction, novel treatment regimes and prevention of diabetes mellitus type 1, rheumatoid arthritis and other systemic rheumatic diseases, autoimmune neurological, gastrointestinal, and liver diseases as well as autoimmune graft rejections. Rare autoimmunopathies such as autoimmune forms of thrombotic microangiopathies, nephropathies, myopathies and cardiomyopathies are also included. Novel therapeutic concepts such as plasma cell targeting, peptide and aptamer based immunotherapy and new vaccination techniques will be presented.

In the future, autoantibodies may be used for a more accurate prediction of diseases development with the hope that early and effective intervention will be able to terminate ongoing pathologic processes. The major challenge for the improvement of predictive diagnostics is the optimization and standardization of autoantibody determinations combined with standardized evaluation studies as well as the search for novel clinical relevant autoantibody specificities. Ideally, cost effective multiparametric assays including novel autoantibodies will be developed. Therefore, the second focus of this volume deals with historical and perspective aspects of autoantibody determinations, the role of immunofluorescence in autoantibody detection, novel assays for autoimmune diagnostics and multiplex immunoassays.

Hopefully, the data and information described and discussed in this volume will stimulate novel concepts that will further the search for better prediction, prevention and treatment of autoimmune diseases.

The editors

From prediction to prevention of autoimmune diseases – Role of autoantibodies

Karsten Conrad

Institute of Immunology, Medical Faculty of the Technical University Dresden,
Germany

E-mail: K_Conrad@mail.zih.tu-dresden.de

Abstract

More and more autoantibodies (AAb) have become important biomarkers for the diagnosis, differential diagnosis, prognosis and in some circumstances monitoring of autoimmune diseases. Furthermore, it has been shown that disease specific AAb may be detectable in preclinical stages. However, their potential role in the very early diagnosis or risk assessment of disease development has to be further evaluated. Hopefully, the more accurate prediction of diseases by AAb — perhaps in combination with other biomarkers — will lead to early and effective interventions that are able to terminate ongoing pathologic processes.

1 Introduction

Up to now more than 100 clinically distinct diseases have been identified in which autoimmune responses participate significantly as the initial cause or as a contributor (Table 1). With the exception of rheumatoid arthritis and autoimmune thyroid diseases most of these entities are rare or very rare but considered together autoimmune diseases (AID) affect approximately 5 percent of the population in industrialized countries (1). As major contributors to morbidity and mortality, the cumulative economic and social impact of AID approaches that of cardiovascular disease and cancer. The initiation and development of most AID are very complex processes. There are manifold pathogenic processes and disease accelerating factors that are thought to lead to the development and manifestations of an AID. Accordingly, we speak about autoimmune pathogenesis as a “mosaic” that involves definite genetic and environmental factors with individually different expression and effectiveness (2). Although the past decades of research on the immune system

have yielded a wealth of new information and extraordinary growth in conceptual understanding many of the factors involved in autoimmune pathogenesis have not been identified yet. Another problem regarding medical care and research is that AID often shows long preclinical phases, which can hardly be studied as clinical signs and symptoms are (still) absent. Interestingly, disease specific AAb can be detected prior to diagnosis and before symptoms draw an individual to medical attention. Thus, such AAb may serve as markers of early diagnosis or prediction of the development of a disease. If we identify factors and mechanisms involved in these early stages of disease development, strategies can be established to prevent disease manifestation or to alleviate or cure AID even before eventually identifying their original cause (3).

2 Autoimmune diseases – Definition and classification

Unfortunately, there is no generally valid and practicable definition to categorize a disease as autoimmune. The revised Witebsky-Rose criteria (4) are the most scientific one to classify autoimmune diseases (AID), but the spectrum of relevant criteria is hardly to identify in diseases assumed to be autoimmune in nature. A more practicable, but not perfect, definition was formulated by Feltcamp (5). According to his definition, an AID is *“a disease characterized by a significantly increased frequency of autoantibodies in significantly increased titres if compared to healthy local controls, matched for sex and age.”* This is true for the majority of known AID, but also for some non-autoimmune diseases (e.g. tumors). Furthermore, T cell mediated AID with no (or not yet identified) specific AAb responses can not be classified as autoimmune by this definition. In conclusion, all diseases in which autoimmune mechanisms play a major role in disease development, should be regarded as AID compared to diseases with no or a secondary autoimmune response. However, a secondary autoimmune response may also be involved in the pathogenesis and therefore of diagnostic or predictive relevance. From the etiopathological point of view, AID are diseases in which adaptive immune responses play the predominant role whereas autoinflammatory diseases are characterized by self-directed inflammation that are independent of adaptive immunity. Because many noninfectious inflammatory diseases can not clearly defined as primary autoimmune or primary autoinflammatory, an autoinflammatory-autoimmune continuum has been postulated that offers an comprehensive classification of immunological disease and a better understanding of the pathogenesis and treatment of self-directed inflammation (6). In particular cases (e.g., Crohn’s disease) it has to be clarified if autoimmune responses are only secondary to autoinflammation or are signs of a potential autoimmune disease subset. So far, more than 100 different diseases may be classified as classic AID or as probable AID within the autoinflammatory-autoimmune continuum (see Table 1).

Table 1. Autoimmune diseases and their characteristic autoantibodies. Autoantibodies shown in red have been demonstrated to be predictive or potentially predictive markers in retrospective and/or prospective studies (see (9–24)).

Autoimmune disease	Autoantibodies against
Blood diseases	
Aplastic anemia	moesin, kinectin, PMS1, DRS-1
Autoimmune hemolytic anemia (AIHA)	erythrocyte surface antigens
Autoimmune hemophilia	factor VIII, factor IX
Autoimmune lymphoproliferative syndrome (ALPS)	thrombocyte and neutrophil surface antigens (among others)
Autoimmune neutropenia	neutrophil surface antigens
Autoimmune thrombocytopenia (AITP, ITP)	thrombocyte surface antigens
Evans syndrome	thrombocyte, erythrocyte and neutrophil surface antigens
Heparin induced thrombocytopenia (HIT) type II	platelet factor 4/heparin complex
Pernicious anemia	H⁺/K⁺-ATPase, intrinsic factor
Endocrine diseases	
Autoimmune adrenalitis (Addison's disease)	21-hydroxylase
Autoimmune hyperparathyroidism	calcium sensitive receptor (CaSR) (stimulating AAb)
Autoimmune hypoparathyroidism	calcium sensitive receptor (CaSR) (inhibiting AAb)
Autoimmune hypophysitis	pituitary gland antigens
Autoimmune hyperthyroidism (Graves' disease)	TSH receptor

Autoimmune polyglandular syndromes type 1	P450scc, 17 α - and 21-hydroxylase, enzymes of neurotransmitter synthesis (among others)
Autoimmune polyglandular syndromes type 2	21-hydroxylase, TSH receptor, thyreoperoxidase, GAD (among others)
Autoimmune thyroiditis (Hashimoto's thyroiditis)	thyreoperoxidase (TPO), thyroglobulin (Tg)
Diabetes insipidus centralis	vasopressin producing cell antigens
Diabetes mellitus type 1	GAD, IA2, Insulin, ZnT8
Diabetes mellitus type 3G	insulin receptor
Insulin autoimmune syndrome (IAS)	insulin
Insulin resistance type B	insulin receptor
IPEX syndrome	enterocyte antigens (among others)
Ovarian insufficiency	P450scc, 17 α -hydroxylase, pituitary gland antigens
Ear diseases	
Autoimmune inner ear diseases	heat shock protein 70
Eye diseases	
Autoimmune uveitis	
Autoimmune retinopathy, incl. paraneoplastic forms (CAR, MAR)	retinal antigens (e.g. recoverin, carbonic anhydrase II)
Sympathetic ophthalmia	

Gastrointestinal diseases	
Autoimmune enteropathy	enterocyte and goblet cell antigens
Autoimmune gastritis	H ⁺ /K ⁺ -ATPase, intrinsic factor
Celiac disease	tTG
Crohn's disease	ASCA, pancreatic acinus cells/GP2
Ulcerative colitis	ANCA, goblet cell antigens
Heart diseases	
Chagas cardiomyopathy	beta 1 adrenergic and/or muscarinic type 2 acetylcholine receptor
Congenital heart block	Ro/SS-A, La/SS-B
Dilated cardiomyopathy	beta 1 adrenergic and/or muscarinic type 2 acetylcholine receptor
Kidney diseases	
Goodpasture syndrome/anti-GBM nephritis	collagen type IV (NC1 domain) of GBM
IgA nephropathy (Berger disease)	aberrantly glycosylated IgA1
Membranous glomerulonephritis (MN)	phospholipase A2 receptor
Membranoproliferative glomerulonephritis (MPGN)	complement factors C1q, B and H, C3 convertase C3bBb (C3NeF)
Pauci-immune glomerulonephritis	myeloperoxidase, proteinase 3, LAMP-2

Liver diseases	
Autoimmune hepatitis	cytochrome P450 2D6 (LKM1), formiminotransferase cyclodeaminase (LC1), F-actin, UGA-suppressor serine tRNA associated protein (SLA/LP), nuclear antigens, ASGPR
Primary biliary cirrhosis	PDH-E2 (AMA-M2), sp100, gp210
Primary sclerosis cholangitis	neutrophil antigen(s)
Neurological diseases	
Autoimmune autonomic gangliopathies (AAG)	ganglionic nAChR
Autoimmune encephalitides (more than 5 different forms, e.g. Paraneoplastic limbic encephalitis, Anti-NMDA receptor encephalitis)	glutamate (NMDA, AMPA) receptors, onconeuroal antigens, Lgi1
Autoimmune (poly)neuropathies (more than 10 different entities, e.g. Guillain-Barré syndrome, multi-focal motor neuropathy)	gangliosides (e.g. GM1, GQ1b), sulfatides
Cerebral folate deficiency syndrome (CFDS)	folate receptor
Multiple sclerosis	(myelin oligodendrocyte glycoprotein)
Narcolepsy	Tribbles homolog 2 protein (Trib2)
Neuromyelitis optica (NMO)	aquaporin 4
Paraneoplastic neurological syndromes (e.g. cerebellar degeneration)	onconeuroal antigens

Neuromuscular diseases	
Arthrogryposis multiplex congenital (AMC)	γ subunit of fetal nAChR
Lambert-Eaton myasthenic syndrome (LEMS)	P/Q type voltage-gated calcium channels
Myasthenia gravis (MG)	$\alpha 1$ subunit of nAChR, MuSK, titin, ryanodine
Morvan's syndrome	Caspr2, Lgi1
Neuromyotonia (Isaac's syndrome)	Caspr2
Stiff person syndrome	GAD
Skin diseases	
Alopecia areata	hair-follicle specific proteins
Autoimmune blistering diseases (more than 10 different entities, e.g. dermatitis herpetiformis, pemphigus vulgaris)	tTG, desmosomal (e.g. desmoglein 1 and 3) and hemidesmosomal antigens, collagen VII
Acquired angioedema type II	C1 inhibitor
Autoimmune urticaria	Fc ϵ receptor of type I (Fc ϵ RI)
Hypocomplementemic urticaria-vasculitis syndrome (HUVS)	C1q
Vitiligo	melanocyte specific tyrosinase, melanin metabolism influencing antigens

Systemic AID	
Rheumatoid arthritis	RF, ACPA, RA33
Connective tissue diseases	
Systemic lupus erythematosus	dsDNA, Sm, U1-RNP, ribosomal P-protein, Ro/SS-A, La/SS-B
Systemic sclerosis	CENP-A,-B, Scl70
Sjögren's syndrome	Ro/SS-A, La/SS-B
Mixed connective tissue syndrome	U1-RNP
Autoimmune myositides	tRNA synthetases, Mi-2, signal recognition particle
Overlap syndromes	exosomal antigens, Ku
Antiphospholipid syndrome	phospholipids (PL) and PL associated proteins
ANCA associated vasculitides (AAV)	proteinase 3 (PR3), myeloperoxidase (MPO)
IgG4-associated sclerosing disease	carboanhydrase II
Thrombotic microangiopathies	
Hemolytic uremic syndrome (HUS)	complement factor H, B
Thrombotic thrombocytopenic purpura (TTP)	ADAMTS13

3 Autoantibodies in the prediction of disease development

Autoantibodies with high disease specificity are important markers for the differential diagnosis of autoimmune diseases (AID) and they are often a key element in the classification or diagnostic criteria for these diseases (reviewed in (7, 8)). In many cases, an AID can be virtually ruled out if the AAb or a combination of certain AAb are negative. For example, only rare or unusual cases of systemic lupus erythematosus (SLE) or mixed connective tissue disease (MCTD) have a negative AAb test and the vast majority of type 1 diabetes mellitus (T1DM) have AAb directed against islet cells, glutamic acid decarboxylase, insulin, IA2 and/or ZnT8. The diagnosis can be often confirmed by detection of AAb if there are typical clinical symptoms, even if the classification or diagnostic criteria of the disease are not completely fulfilled (9). As early adequate therapy is necessary for optimal control of disease progression, the diagnosis should be secured at the earliest possible phase of the disease. For this, the determination of AAb that have high disease specificity and high predictive value becomes more and more important.

Both retrospective and prospective studies have clearly shown that disease specific AAb can be detected months to several years before clinical manifestations of the corresponding disease (reviewed in (10–20)). One of the challenges for retrospective studies is that sera from patients are ideally required before the onset of clinical manifestations. Thus, with the exception of anecdotes and case studies, retrospective cohort studies are difficult and seldom done. Extensive studies have been performed regarding AAb in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and chronic inflammatory bowel diseases (9, 21–24). In these studies, the investigators had access to serum banks that were created for other purposes. The aim of retrospective studies is to show how often and how long the disease specific AAb are detectable before clinical manifestations. On the other hand, the aim of prospective studies consists of determining the risk that AAb-positive individuals will have in developing the corresponding disease. Prospective studies are — with the exception on studies of type 1 diabetes development — mainly done with cohorts of individuals that have an increased risk to develop an AID. Middle to high titred disease specific AAb in persons of tested cohorts may indicate an underlying autoimmune pathological process. Indeed, a high predictive value regarding disease development has been shown in prospective studies for islet cell, insulin, GAD and IA2 antibodies (diabetes mellitus type 1), adrenal cortex/21-hydroxylase antibodies (Addison's disease), thyroperoxidase antibodies (Hashimoto thyroiditis), type 2 antimitochondrial antibodies (primary biliary cirrhosis), tissue transglutaminase antibodies (celiac disease), rheumatoid factors (RF) and CCP antibodies (rheumatoid arthritis) as well as for Ro/SS-A and La/SS-B antibodies (autoimmune rheumatic diseases) (reviewed in (19)). However, the potential role of AAb in the very early diagnosis or risk assessment of disease development has to be further evaluated as a major prerequisite for prevention studies.

It is important to mention, that AAb may not only indicate the probable development of an appropriate AID (see Table 1) but also the course of the disease and therefore may influence disease management. Furthermore, heterogeneous conditions such as the spectrum of autoimmune myositides can be differentiated in distinct clinicoserological phenotypes that may help to predict complications of disease, prognosis, and responses to treatment (25).

4 Prevention of autoimmune diseases

To prevent the development of AID, the following prerequisites have to be fulfilled: (i) A high relevance of AAb (perhaps in combination with other biomarkers) for risk assessment of disease development has to be demonstrated by large prospective studies. For example, highly credible studies indicate that the risk for the development of type 1 diabetes in children and adults can be predicted with a high sensitivity and specificity by the determination of diabetes specific AAb (26–28). (ii) Knowledge of factors critically involved in pathogenic or repair processes. The elimination of environmental risk factors such as smoking or the application of potential protective factors such as vitamin D may help to prevent disease development in AAb positive persons, for instance to prevent manifestation of rheumatoid arthritis in RF or CCP antibody positive persons (29, 39). (iii) Knowledge of major pathomechanisms leading to disease manifestation to find optimal strategies to influence these mechanisms. The genetic predisposition, which determines the possible immune reactivities and regulatory mechanisms, is an important but not a sufficient component of autoimmune pathogenesis. Exogenic factors (e.g. viral or bacterial infections, xenobiotics, ultraviolet light) are necessary for the initiation and expression of the autoimmune condition as well as the chronicity and progression of the immunopathogenesis. The knowledge of the specific interplay between genetic and environmental factors will show possibilities for preventive interventions.

The development of an AID may be divided into different stages (Figure 1): I. The induction phase is characterized by the generation of disease specific autoimmune phenomena (autoreactive T cells and/or AAb). II. In the preclinical phase the autoimmune phenomena exert pathogenetic effects that are influenced by various triggering or accelerating as well as regulating factors (e.g., regulatory T cells). III. The progressive effectiveness of autoimmune mechanisms leads in the clinical phase to corresponding symptoms as well as to diagnostic relevant paraclinical alterations. For example, the clinical manifestation of type 1 diabetes only occurs after 80–90 % of the insulin producing β cells of the pancreas being immunologically destroyed. The course of disease development may be influenced at different stages by influencing triggering and effector as well as regulating mechanisms of the particular immunopathogenesis. The better the knowledge of these




Figure 1. Simplified scheme of the stages of the development of autoimmune diseases (AID). The development of a classic AID starts with the induction of a more or less disease specific autoimmune response. Depending on additional factors, autoimmune mechanisms lead to chronic inflammation of the appropriate tissue (e.g., pancreatic islet cells in type 1 diabetes, adrenal cortex cells in Addison's disease) or to chronic interference with biological structures (e.g., stimulation or blocking of receptors or regulatory proteins). If regulatory processes and/or repair mechanisms are effective, the pathomechanism may be stopped and no disease develops. Otherwise the process is ongoing up to the clinical manifestation of the disease (e.g. type 1 diabetes becomes manifest, if 80–90% of the insulin producing cells are destroyed). The course of disease development may be influenced at different stages by endogeneous and environmental factors that act as trigger, effector or regulator of the particular immunopathogenesis. Because disease specific autoantibodies (AAb) are detectable not only in AAb mediated but also in most T cell mediated AID (e.g., type 1 diabetes) at early stages, they are good indicators for disease development and their positivity may serve as a criterion for predictive intervention studies. Furthermore, clinically heterogeneous AID (e.g., systemic sclerosis, autoimmune myositis) can be differentiated in distinct clinicoserological phenotypes that may help to predict complications of disease, prognosis, and responses to treatment.

mechanisms and the earlier the intervention the better should be the possibility to prevent disease manifestation.

5 Perspectives

As already mentioned, a key characteristic of many AID is the presymptomatic production of disease specific autoantibodies. Therefore, the presence of disease specific AAb may indicate preclinical autoimmune mechanisms. Because the risk of disease development depends on further factors, AAb determinations alone may not be sufficient enough for risk assessment of most AID. Persons may be AAb positive without development of the appropriate disease. Therefore, the search for better prediction of disease development is a major challenge to establish predictive intervention studies. Besides AAb characteristics (epitope spreading, isotype, titer, affinity, AAb profiles) the combination of different biomarkers may be helpful. On the other hand, studies on involved genetic (31, 32), hormonal (33) and environmental factors (34, 35) as well as on pathological autoimmune processes may offer new intervention strategies at early stage of disease development (3, 36). Hopefully, the better understanding of autoimmune pathogenesis of certain AID along with novel options for early intervention may help to prevent disease development in risk persons positive for disease specific AAb.

References

- (1) Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. *Clin Immunol Immunopathol* 1997; 84: 223–43.
- (2) Shoenfeld Y, Isenberg D (Editors): *The Mosaic of Autoimmunity (The factors associated with autoimmune diseases)*. Elsevier, Amsterdam-New York-Oxford 1990.
- (3) Williams RC, Jr. Autoimmune disease etiology — a perplexing paradox or a turning leaf? *Autoimmun Rev* 2007; 6: 204–8.
- (4) Rose ER, Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). *Immunol Today* 1993; 14: 426–30.
- (5) Feltcamp TEW. The Mystery of Autoimmune Diseases. In: Shoenfeld Y (ed): *The Decade of Autoimmunity*. Amsterdam, Elsevier Science B.V., 1999: 1–5.
- (6) McGonagle D, McDermott MF. A proposed classification of the immunological diseases. *PLoS Med* 2006; 3: 1242–48.
- (7) Conrad K, Schössler W, Hiepe F: *Autoantibodies in systemic autoimmune disease — A diagnostic reference*. 2nd Edition, Pabst Science Publishers, Lengerich 2007.
- (8) Conrad K, Schössler W, Hiepe F, Fritzler MJ: *Autoantibodies in organ specific autoimmune disease — A diagnostic reference*. Pabst Science Publishers, Lengerich 2011.
- (9) Heinlen LD, McClain MT, Merrill J, Akbarali YW, Edgerton CC, Harley JB, James JA: Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. *Arthritis Rheum* 2007; 56: 2344–51.

- (10) Conrad K, Schössler W, Fritzler MJ. The predictive relevance of autoantibodies. In: K. Conrad, E.K.L. Chan, M.J. Fritzler, U. Sack, Y. Shoenfeld, A. S. Wiik (Eds.). *From Etiopathogenesis to the Prediction of Autoimmune Diseases: Relevance of Autoantibodies*. Pabst Science Publishers, Lengerich 2007, pp16–31.
- (11) Shoenfeld Y, Blank M, Abu-Shakra M, Amital H, Ori Barzilai O, Berkun Y, Bizzaro N, Gilburd B, Zandman-Goddard G, Katz U, Krause I, Langevitz P, Mackay IR, Orbach H, Ram M2, Sherer Y, Toubi E, Gershwin ME. The Mosaic of Autoimmunity: Prediction, Autoantibodies, and Therapy in Autoimmune Diseases – 2008. *IMAJ* 2008; 10: 13–9.
- (12) Shepshelovich D, Shoenfeld Y. Prediction and prevention of autoimmune diseases: additional aspects of the mosaic of autoimmunity. *Lupus* 2006; 15: 183–90.
- (13) Scofield RH. Autoantibodies as predictors of disease. *Lancet* 2004; 363: 1544–46.
- (14) Sarzi-Puttini P, Doria A. Organ specific-autoantibodies: Their role as markers and predictors of disease. *Autoimmun* 2008; 41: 1–10.
- (15) Leslie D, Lipsky P, Notkins AL. Autoantibodies as predictors of disease. *J Clin Invest* 2001; 108: 1417–22.
- (16) Harel M, Shoenfeld Y. Predicting and Preventing Autoimmunity, Myth or Reality? *Ann NY Acad Sci* 2006; 1069: 322–45.
- (17) Fritzler MJ. Challenges to the use of autoantibodies as predictors of disease onset, diagnosis and outcomes. *Autoimmun Rev* 2008; 7: 616–20.
- (18) Tozzoli R. The diagnostic role of autoantibodies in the prediction of organ-specific autoimmune diseases. *Clin Chem Lab Med* 2008; 46: 577–87.
- (19) Bizzaro N. Autoantibodies as predictors of disease: The clinical and experimental evidence. *Autoimmun Rev* 2007; 6: 325–33.
- (20) Bizzaro N, Tozzoli R, Shoenfeld Y. Are We at a Stage to Predict Autoimmune Rheumatic Diseases? *Arthritis Rheum* 2007; 56: 1736–44.
- (21) Aho K, Heliövaara M, Maatela J, Tuomi T, Palosuo T: Rheumatoid factors antedating clinical arthritis. *J Rheumatol* 1991; 18: 1282–84.
- (22) Arbuckle MR, McClain MT, Rubertone MV, Scofield H, Dennis GJ, James JA, Harley JB. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. *N Engl J Med* 2003; 349: 1526–33.
- (23) Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, Wiik A, Shoenfeld Y. Anti-*Saccharomyces cerevisiae* and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel diseases. *Gut* 2005; 54: 1232–36.
- (24) Kurki P, Aho K, Palosuo T, Heliövaara M. Immunopathology of rheumatoid arthritis. Antikeratin antibodies precede the clinical disease. *Arthritis Rheum* 1992; 35: 914–7.
- (25) Betteridge ZE, Gunawardena H, McHugh NJ. Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. *Arthritis Res Ther* 2011; 13: 209 [Epub ahead of print]
- (26) Winter WE, Schatz DA: Autoimmune Markers in Diabetes. *Clin Chem* 2011; 57: 168–75.
- (27) Van Belle T, Coppieters KT, von Herrath MG. Type 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies. *Physiol Rev* 2011; 91: 79–118.
- (28) Ziegler AG, Nepom GT. Prediction and Pathogenesis in Type 1 Diabetes. *Immunity* 2010; 32: 468–78.
- (29) Källberg H, Ding B, Padyukov L, Bengtsson C, Rönnelid J, Klareskog L, Alfredsson L, EIRA Study Group. Smoking is a major preventable risk factor for rheumatoid arthri-

- tis: estimations of risks after various exposures to cigarette smoke. *Ann Rheum Dis* 2011; 70: 508–11.
- (30) Pelajo CF, Lopez-Benitez JM, Miller LC. Vitamin D and autoimmune rheumatic disorders. *Autoimmun Rev* 2010; 9: 507–10.
- (31) Rioux JD, Abbas AK. Paths to understanding the genetic basis of autoimmune disease. *Nature* 2005; 435: 584–9.
- (32) Pascual V, Chaussabel D, Banchereau J. A Genomic Approach to Human Autoimmune Diseases. *Annu Rev Immuno* 2010; 28: 535–71.
- (33) Rubtsov AV, Rubtsova K, Kappler JW, Marrack P. Genetic and hormonal factors in female-biased autoimmunity. *Autoimmun Rev* 2010; 9: 494–8.
- (34) Pollard MK, Per Hultman P, Kono DH. Toxicology of Autoimmune Diseases. *Chem Res Toxicol* 2010; 23: 455–66.
- (35) Christen U, Hintermann E, Holdener M, von Herrath MG. Viral triggers for autoimmunity: Is the “glass of molecular mimicry” half full or half empty?. *J Autoimmun* 2010; 34: 38–44.
- (36) Von Herrath M. Can We Learn From Viruses How to Prevent Type 1 Diabetes? The Role of Viral Infections in the Pathogenesis of Type 1 Diabetes and the Development of Novel Combination Therapies. *Diabetes* 2009; 58: 2–11.

Abbreviations

ACPA, anticitrullinated protein antibody; **ADAMTS13**, a disintegrin and metalloprotease with thrombospondin-1 like domains 13; **AMA-M2**, antimitochondrial antibody type 2; **AMPA**, alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; **ANCA**, anti-neutrophil cytoplasmic antibodies; **ASCA**, anti-*Saccharomyces cerevisiae* antibodies; **ASGPR**, asialoglycoprotein receptor; **C3NeF**, C3 nephritis factor; **CAR**, cancer associated retinopathy; **Caspr2**, contactin-associated protein-like 2; **CCP**, cyclic citrullinated peptide; **GAD**, glutamic acid decarboxylase; **DRS-1**, diazepam-binding inhibitor related protein-1; **GBM**, glomerular basement membrane; **GP2**, glucoprotein 2; **ITP**, idiopathic thrombocytopenic purpura; **IPEX**, immune dysregulation, polyendocrinopathy and enteropathy, X chromosome inherited syndrome; **LAMP-2**, lysosomal-associated membrane protein 2; **LCI**, liver cytosolic 1; **Lgil**, leucine-rich glioma inactivated 1; **LKMI**, liver-kidney microsomal; **MAR**, melanoma associated retinopathy; **MuSK**, muscle-specific receptor tyrosine kinase; **nAChR**, nicotinic acetylcholine receptor; **NMDA**, N-methyl-D-aspartate; **P450ssc**, cytochrome P450 side chain cleavage enzyme; **PDH-E2**, Pyruvate dehydrogenase, subunit E2; **PMS1**, post-meiotic segregation increased 1; **RNP**, ribonucleoprotein; **SLA/LP**, soluble liver antigen/liver-pancreas antigen; **TSH**, thyroid stimulating hormone; **tTG**, tissue transglutaminase.